Loading clinical trials...
Loading clinical trials...
A Phase Ib/II Clinical Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer
Conditions
Interventions
BBI503
Capecitabine
+5 more
Locations
8
United States
Parkview Research Center
Fort Wayne, Indiana, United States
Indiana University Health Goshen
Goshen, Indiana, United States
Indiana University -Ball
Indianapolis, Indiana, United States
Indiana University-SCC
Indianapolis, Indiana, United States
Louisiana State Univesity
New Orleans, Louisiana, United States
US Oncology Research
Fairfax, Virginia, United States
Start Date
September 1, 2015
Primary Completion Date
May 1, 2019
Completion Date
May 1, 2019
Last Updated
November 14, 2023
NCT05468034
NCT04541381
NCT06713993
NCT06043817
NCT01109420
NCT06926283
Lead Sponsor
Sumitomo Pharma America, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions